Best Practice & Research Clinical Rheumatology
Volume 22, Issue 3 , Pages 499-522 , June 2008

Alternative therapies for musculoskeletal conditions

  • Luis Vitetta, BSc (Hons), PhD, GradDip IntgrMed, GradDip NutrEnvMed (Associate Professor and Principal Research Fellow)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +61 7 3240 2903; Fax: +61 7 3240 6858.
  • Flavia Cicuttini, MBBS (Hons), PhD, MSc, DLSHTM, FRACP, FAFPHM (Professor, Monash University, Head, Musculoskeletal Unit DEPM, and Head, Rheumatology Unit)
  • Avni Sali, MBBS, PhD, FRACS, FACS, FACNEM (Professor and Director)

References 

  1. Siebens HC. Musculoskeletal problems as comorbidities. American Journal of Physical Medicine and Rehabilitation. 2007;86:S69–S78
  2. Bergman S. Public health perspective-how to improve the musculoskeletal health of the population. Best Practice and Research. Clinical Rheumatology. 2007;21:191–204
  3. Centers for Disease Control and Prevention (CDC) . Monitoring progress in arthritis management-United States and 25 states, 2003. MMWR Morbidity and Mortality Weekly Report. 2005;54:484–488
  4. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Practice and Research. Clinical Rheumatology. 2006;20:3–25
  5. http://arthritisaustralia.com.au/media/file/Access%20Economics%20Report%202001.pdf[accessed June 2007]
  6. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. The Journal of American Medical Association. 1998;280:1569–1575
  7. MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia costs and beliefs in 2004. Medical Journal of Australia. 2006;184:27–31
  8. Ernst E. Musculoskeletal conditions and complementary/alternative medicine. Best Practice and Research. Clinical Rheumatology. 2004;18:539–556
  9. Nagle DG, Ferreira D, Zhou YD. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry. 2006;67:1849–1855
  10. Hardin SR. Cat's claw: an Amazonian vine decreases inflammation in osteoarthritis. Complementary Therapies in Clinical Practice. 2007;13:25–28
  11. Ahmed S, Anuntiyo J, Malemud CJ, et al. Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. Evidence Based Complementary and Alternative Medicine. 2005;2:301–308
  12. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Advances in Experimental Medicine and Biology. 2007;595:453–470
  13. Canter PH, Lee HS, Ernst E. A systematic review of randomised clinical trials of Tripterygium wilfordii for rheumatoid arthritis. Phytomedicine. 2006;13:371–377
  14. Curtis CL, Harwood JL, Dent CM, et al. Biological basis for the benefit of nutraceutical supplementation in arthritis. Drug Discovery Today. 2004;9:165–172
  15. Mur E, Hartig F, Eibl G, et al. Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. The Journal of Rheumatology. 2002;29:656–658
  16. Sandoval M, Okuhama NN, Zhang XJ, et al. Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine. 2002;9:325–337
  17. Chrubasik JE, Roufogalis BD, Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. Phytotheraphy Research. 2007;21:675–683
  18. Gagnier JJ, Chrubasik S, Manheimer E. Harpgophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complementary and Alternative Medicine. 2004;4:13
  19. Fiebich BL, Heinrich M, Hiller KO, et al. Inhibition of TNF-alpha synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69. Phytomedicie. 2001;8:28–30
  20. Huang TH, Tran VH, Duke RK, et al. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation. Journal of Ethnopharmacology. 2006;104:149–155
  21. Chrubasik S, Conradt C, Black A. The quality of clinical trials with Harpagophytum procumbens. Phytomedicine. 2003;10:613–623
  22. Chrubasik S, Model A, Black A, et al. A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. Rheumatology. 2003;42:141–148
  23. Gagnier JJ, van Tulder MW, Berman B, et al. Herbal medicine for low back pain: a Cochrane review. Spine. 2007;32:82–92
  24. Tao X, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheumatic Diseases Clinics of North America. 2000;57:1221–1227
  25. Tao X, Younger J, Fan FZ, et al. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2002;46:1735–1743
  26. Tao X, Cush JJ, Garret M, Lipsky PE. A phase I study of ethyl acetate extract of the chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. The Journal of Rheumatology. 2001;28:2160–2167
  27. Cibere J, Deng Z, Lin Y, et al. A randomized double blind, placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: reanalysis using logistic regression analysis. The Journal of Rheumatology. 2003;30:465–467
  28. Aggarwal BB, Shishodia S. Suppression of the nuclear factor-kB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Annals of the New York Academy of Sciences. 2004;1030:434–441
  29. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of turmeric (Curcuma longa). Journal of Alternative Complementary Medicine. 2003;9:161–168
  30. Joe B, Rao UJ, Lokesh BR. Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin. Molecular and Cellular Biochemistry. 1997;169:125–134
  31. Mukhopadhyay A, Basu N, Ghatak N, et al. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents and Action. 1982;12:508–515
  32. Deodhar SD, Sethi R, Srimal RC. Preliminary studies on antirheumatic activity of curcumin. The Indian Journal of Medicine Research. 1980;71:632–634
  33. Ippoushi K, Azuma K, Ito H, et al. [6]-Gingerol inhibits nitric oxide synthesis in activated J774.1 mouse macrophages and prevents peroxynitrite-induced oxidation and nitration reactions. Life Sciences. 2003;73:3427–3437
  34. Thomson M, Al-Qattan KK, Al-Sawan SM, et al. The use of ginger (Zingiber officinale Rosc.) as a potential anti-inflammatory and antithrombotic agent. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 2002;67:475–478
  35. Jolad SD, Lantz RC, Solyom AM, et al. Fresh organically grown ginger (Zingiber officinale): composition and effects on LPS-induced PGE2 production. Phytochemistry. 2004;65:1937–1954
  36. Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis and Rheumatism. 2001;44:2531–2538
  37. Bliddal H, Rosetzsky A, Schlichting P, et al. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage. 2000;8:9–12
  38. Srivastava KC, Mustafa T. Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Medical Hypotheses. 1992;39:342–348
  39. Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ (Clinical Research Ed.). 2004;328:991
  40. Zhang B, Li JB, Zhang DM, et al. Analgesic and anti-inflammatory activities of a fraction rich in gaultherin isolated from Gaultheria yunnanensis. Biological and Pharmaceutical Bulletin. 2007;30(3):465–469
  41. Zhang B, He XL, Ding Y, et al. Gaultherin, a natural salicylate derivative from Gaultheria yunnanensis: towards a better non-steroidal anti-inflammatory drug. European Journal of Pharmacology. 2006;530(1–2):166–171
  42. Chan TY. The risk of severe salicylate poisoning following the ingestion of topical medicaments or aspirin. Postgraduate Medical Journal. 1996;72:109–112
  43. Ernst E, Chrubasik S. Phyto-anti-inflammatories. A systematic review of randomized, placebo-controlled, double-blind trials. Rheumatic Diseases Clinics of North America. 2000;26:13–27
  44. Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Medica. 2006;72:1100–1116
  45. Gayathri B, Manjula N, Vinaykumar KS, et al. Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFalpha, IL-1beta, NO and MAP kinases. International Immunopharmacology. 2007;7(4):473–482
  46. Kimmatkar N, Thawani V, Hingorani L, et al. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee – a randomized double blind placebo controlled trial. Phytomedicine. 2003;10:3–7
  47. Sontakke S, Thawani S, Pimpalkhute P, et al. Open, randomized, controlled clinical trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian Journal of Pharmacology. 2007;39:27–29
  48. Setty AR, Sigal LH. Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Seminars in Arthritis and Rheumatism. 2005;34:773–784
  49. Rossnagel K, Roll S, Willich SN. The clinical effectiveness of rosehip powder in patients with osteoarthritis. A systematic review. MMW Fortschritte der Medizin. 2007;149:51–56
  50. Chrubasik C, Duke RK, Chrubasik S. The evidence for clinical efficacy of rose hip and seed: a systematic review. Phytotheraphy Research. 2006;20:1–3
  51. Winther K, Apel K, Thamsborg G. A powder made from seeds and shells of a rose-hip subspecies (Rosa canina)reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial. Scandinavian Journal of Rheumatology. 2005;34:302–308
  52. Wang Y, Prentice LF, Vitetta L, et al. The effect of nutritional supplements on osteoarthritis. Alternative Medicine Review. 2004;9:275–296
  53. Vlad SC, Lavalley MP, McAlindon TE, et al. Glucosamine for pain in osteoarthritis: Why do trial results differ?. Arthritis and Rheumatism. 2007;56:2267–2277
  54. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews. 2005;(2):CD002946
  55. Poolsup N, Suthisisang C, Channark P, et al. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Annals of Pharmacotherapy. 2005;39:1080–1087
  56. Towheed TE, Anastassiades TP, Shea B, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews. 2001;(1):CD002946. Review
  57. Distler J, Anguelouch A. Evidence-based practice: review of clinical evidence on the efficacy of glucosamine and chondroitin in the treatment of osteoarthritis. Journal of the American Academy of Nurse Practitioners. 2006;18:487–493
  58. Reginster JY, Bruyere O, Neuprez A. Current role of glucosamine in the treatment of osteoarthritis. Rheumatology. 2007;46:731–735
  59. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. The New England Journal of Medicine. 2006;354:795–808
  60. Oliviero U, Sorrentino GP, De Paola P, et al. Effects of the treatment with Matrix on elderly people with chronic articular degeneration. Drugs under Experimental and Clinical Research. 1991;17:45–51
  61. Conrozier T. Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6). La Presse Médicale. 1998;27:1862–1865
  62. Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage. 1998;6:39–46
  63. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 1998;6:31–36
  64. Mazieres B, Combe B, Phan Van A, et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. The Journal of Rheumatology. 2001;28:173–181
  65. Morreale P, Manopulo R, Galati M, et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. The Journal of Rheumatology. 1996;23:1385–1391
  66. Mathieu P. Radiological progression of internal femoro-tibial osteoarthritis in gonarthrosis. Chondro-protective effect of chondroitin sulfates ACS4-ACS6. Presse Medicale. 2002;31:1386–1390
  67. Pipitone VR. Chondroprotection with chondroitin sulfate. Drugs under Experimental and Clinical Research. 1991;17:3–7
  68. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine. 2007;146:580–590
  69. Bello AE, Oesser S. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. Current Medical Research and Opinion. 2006;22:2221–2232
  70. Moskowitz RW. Role of collagen hydrolysate in bone and joint disease. Seminars in Arthritis and Rheumatism. 2000;30:87–99
  71. Adam M. Therapy for osteoarthritis: which effects have preparations of gelatin?. Therapiewoche. 1991;38:2456–2461
  72. Usha PR, Naidu MUR. Randomised, double-blind, parallel, placebo- controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clinical Drug Investigation. 2004;24:353–363
  73. Kim LS, Axelrod LJ, Howard P, et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage. 2006;14:286–294
  74. Soeken K, Lee WL, Bausell RB, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. The Journal of Family Practice. 2002;5:425–430
  75. Tavoni A, Vitali C, Bombardieri S, et al. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind cross-over study. American Journal of Medicine. 1987;83:107–110
  76. Ameye LG, Chee WS. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Research Therapy. 2006;8:R127
  77. Cobb CS, Ernst E. Systematic review of a marine nutriceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus. Clinical Rheumatology. 2006;25:275–284
  78. Blotman F, Maheu E, Wulwik A, et al. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Revue Du Rhumatisme (English Ed.). 1997;64:825–834
  79. Appelboom T, Schuermans J, Verbruggen G, et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scandinavian Journal of Rheumatology. 2001;30:242–247
  80. Maheu E, Mazieres B, Valat JP, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis and Rheumatism. 1998;41:81–91
  81. Lequesne M, Maheu E, Cadet C, et al. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis and Rheumatism. 2002;47:50–58
  82. Ernst E. Avocado-soybean unsaponifiables (ASU) for osteoarthritis - a systematic review. Clinical Rheumatology. 2003;22:285–288
  83. Manheimer E, Linde K, Lao L, et al. Meta-analysis: acupuncture for osteoarthritis of the knee. Annals of Internal Medicine. 2007;146:868–877
  84. White A, Foster NE, Cummings M, et al. Acupuncture treatment for chronic knee pain: a systematic review. Rheumatology. 2007;46:384–390
  85. Kwon YD, Pittler MH, Ernst E. Acupuncture for peripheral joint osteoarthritis: a systematic review and meta-analysis. Rheumatology. 2006;45:1331–1337
  86. Morone NE, Greco CM. Mind-body interventions for chronic pain in older adults: a structured review. Pain Medicine. 2007;8:359–375
  87. Astin JA. Mind-body therapies for the management of pain. The Clinical Journal of Pain. 2004;20:27–32

PII: S1521-6942(07)00140-4

doi: 10.1016/j.berh.2007.12.007

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 3 , Pages 499-522 , June 2008

Article Tools

* Image Usage & Resolution